Therapeutic strategies for high-dose vasopressor-dependent shock

31Citations
Citations of this article
96Readers
Mendeley users who have this article in their library.

Abstract

There is no consensual definition of refractory shock. The use of more than 0.5 mcg/kg/min of norepinephrine or epinephrine to maintain target blood pressure is often used in clinical trials as a threshold. Nearly 6% of critically ill patients will develop refractory shock, which accounts for 18% of deaths in intensive care unit. Mortality rates are usually greater than 50%. The assessment of fluid responsiveness and cardiac function can help to guide therapy, and inotropes may be used if hypoperfusion signs persist after initial resuscitation. Arginine vasopressin is frequently used in refractory shock, although definite evidence to support this practice is still missing. Its associations with corticosteroids improved outcome in observational studies and are therefore promising alternatives. Other rescue therapies such as terlipressin, methylene blue, and high-volume isovolemic hemofiltration await more evidence before use in routine practice. © 2013 Estevão Bassi et al.

Cite

CITATION STYLE

APA

Bassi, E., Park, M., & Azevedo, L. C. P. (2013). Therapeutic strategies for high-dose vasopressor-dependent shock. Critical Care Research and Practice. https://doi.org/10.1155/2013/654708

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free